High-dose antithrombin III in severe sepsis: A randomized controlled trial

JAMA

Volumn 286, Issue 15, 2001, Pages 1869-1878

  Warren, Brian L ^a   Eid, Alain ^b   Singer, Pierre ^c   Pillay, Subramanion S ^d   Carl, Peder ^e   Novak, Ivan ^f   Chalupa, Pavel ^g   Atherstone, Alan ^h   Pénzes, Istvan ⁱ   Kübler, Andrezej ^j   Knaub, Sigurd ^k   Keinecke, Heinz Otto ^k   Heinrichs, Hubert ^k   Schindel, Fritz ^k   Juers, Mathias ^k   Bone, Roger C ^l   Opal, Steven M ^m  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c RABIN MEDICAL CENTER   (Israel)

^d Department of Gastroenterology   (South Africa)

^e HVIDOVRE HOSPITAL   (Denmark)

^f CHARLES UNIVERSITY   (Czech Republic)

^g Clinic of Children's Infectious Diseases   (Czech Republic)

^h Frere Hospital   (South Africa)

ⁱ SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^j WROCLAW MEDICAL UNIVERSITY   (Poland)

^k SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^l RUSH UNIVERSITY MEDICAL CENTER   (United States)

^m BROWN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; HEPARIN; PLACEBO; ANTICOAGULANT AGENT; SERINE PROTEINASE INHIBITOR;

ADULT; ARTICLE; BLEEDING; BLOOD CLOTTING; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTIC SHOCK; SURVIVAL TIME; THROMBOGENESIS; TREATMENT OUTCOME; DRUG INTERACTION; MULTICENTER STUDY; SURVIVAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOSIS;

ADULT; ANTICOAGULANTS; ANTITHROMBIN III; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HEPARIN; HUMANS; MALE; MULTIPLE ORGAN FAILURE; SERINE PROTEINASE INHIBITORS; SHOCK, SEPTIC; SURVIVAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOSIS;

EID: 0035904368     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.15.1869     Document Type: Article

References (46)

1. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome
2. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock
3. Time course of hemostatic abnormalities in sepsis and its relation to outcome
4. Pathogenesis of disseminated intravascular coagulation in sepsis
5. Septic shock, multiple organ failure, and disseminated intravascular coagulation: Compared patterns of antithrombin III, protein C, and protein S deficiencies
6. Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock
7. Sepsis/septic shock: Participation of the microcirculation: An abbreviated review
8. Experimemal endotoxin in humans: An analysis of cytokine release and coagulation, fibrinolytic and complement pathways
9. Activation of coagulation after administration of TNF in normal subjects
10. Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure
11. Some properties of antithrombin III and its concentrations in human plasma
12. Clinical relevance of antithrombin deficiencies
13. The contact system contributes to hypotension but not to disseminated intravascular coagulation in lethal bacteremia
14. Antithrombin III: Its physiologic importance and role in DIC
15. Initiation of tissue factor pathway of coagulation in the presence of heparin: Control by antithrombin III and tissue factor pathway inhibitor
16. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor
17. Antithrombin reduces ischermia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin
18. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells
19. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not thrombin-dependent prostacyclin production in human endothelial cells
20. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III
21. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats
22. Heparin therapy in bacterial septicemia
23. Antithrombin III transfusion in disseminated intravascular coagulation
24. Factor VII antithrombin III activity during sepsis and septic shock in neutropenic patients
25. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion
26. Antithrombin III in animal models of sepsis and organ failure
27. Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin
28. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation
29. Antithrombin III supplementation in severe sepsis: Beneficial effects on organ dysfunction
30. Antithrombin III (AT III) replacement therapy in patients with sepsis and/or post surgical complications: A double-blind, randomized, multicenter trial
31. Anti-thrombin III in patients with severe sepsis: A randomized, placebo-controlled, double-blind, multicenter trial plus a meta-analysis on all randomized-placebo-controlled, double-blind trials with antithrombin III in severe sepsis
32. The logistic organ dysfunction system: A new way to assess organ dysfunction in the intensive care unit
33. Simplified acute physiology score (SAPS II) based on a European/North American multicenter study
34. Customized probability models for early severe sepsis in adult intensive care patients
35. Interim analyses in randomized clinical trials
36. An improved approximate formula for calculation of sample sizes for comparing two binomial distributions
37. The use of interim analyses for sample size adjustment
38. Clinical trials for severe sepsis: Past failures and future hopes
39. Therapeutic rationale for antithrombin in sepsis
40. Clinical trial results with antithrombin III in sepsis
41. Antithrombin III in patients with severe sepsis: A pharmacokinetic study
42. Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway
43. Binding of antithrombin to endothelial surface is crucial for its antiinflammatory effects after LPS-challenge
44. Efficacy and safety of recombinant human activated protein C for severe sepsis